Saturday, 31 August 2013

New Approach to Prevent Diabetes-Induced Birth Defects 

A research team at the University of Maryland School of Medicine has identified a cell signaling pathway which plays a significant role in causing developmental defects of the fetal spinal cord and brain in babies of women with diabetes  (University of Maryland Medical Center)




Video presentation


Richness of human gut microbiome correlates with metabolic markers

Individuals with a low bacterial richness (23% of the population) are characterized by more marked overall adiposity, insulin resistance and dyslipidaemia and a more pronounced inflammatory phenotype when compared with high bacterial richness individuals (Nature)


GABA regulates both the survival and replication of human ß-cells

These actions, together with the anti-inflammatory properties of GABA, suggest that modulation of peripheral GABA-Rs may represent a promising new therapeutic strategy for improving ß-cell survival following human islet transplantation and increasing ß-cells in patients with diabetes (Diabetes)

Friday, 30 August 2013

Fruit consumption and risk of type 2 diabetes

Our findings suggest the presence of heterogeneity in the associations between individual fruit consumption and risk of type 2 diabetes (BMJ)


Relationship of Glycated Albumin to Blood Glucose and Glycated Hemoglobin (HbA1C) Values and to Retinopathy, Nephropathy and Cardiovascular Outcomes in the DCCT/EDIC Study

In the case-cohort analyses, HbA1c and GA had similar associations with retinopathy and nephropathy, which were strengthened when both measures were considered together (Diabetes)



Thursday, 29 August 2013

Fluvastatin-induced reduction of oxidative stress ameliorates diabetic cardiomyopathy in association with improving coronary microvasculature

These results suggest that beneficial effects of fluvastatin on diabetic cardiomyopathy might result, at least in part, from improving coronary microvasculature through reduction in myocardial oxidative stress and upregulation of angiogenic factor (Heart and Vessels)



Association of Barrett's Esophagus With Type II Diabetes Mellitus

In a large population-based case-control study, DM2 was a risk factor for BE, independent of obesity and other risk factors. These data suggest that metabolic pathways related to DM2 should be explored in BE pathogenesis and esophageal carcinogenesis (Clinical Gastroenterology and Hepatology)



Wednesday, 28 August 2013

Glycosylated Fibronectin as a First-Trimester Biomarker for Prediction of Gestational Diabetes

First-trimester serum concentrations of glycosylated fibronectin, adiponectin, high-sensitivity C-reactive protein, and placental lactogen were significantly associated with Gestational Diabetes (Obstetrics & Gynecology)


Children followed in the TEDDY study are diagnosed with type 1 diabetes at an early stage of disease

Close follow-up of children with genetic risk enables early detection of T1D. Risk factors for rapid development of diabetes in this young population were first-degree relatives status and autoantibodies to glutamic acid decarboxylase (GADA), insulinoma-associated protein 2 (IA-2) and insulin (IAA) (Pediatric Diabetes)


Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine

Patients with T2DM initiating insulin glargine treatment showed low rates of hypoglycemia, especially when using a disposable pen device. Hypoglycemia-related costs were low, contributing a very small proportion to overall diabetes-related healthcare costs (Journal of Medical Economics)



Tuesday, 27 August 2013

RU28318, an Aldosterone Antagonist, in Combination with an ACE Inhibitor and Angiotensin Receptor Blocker Attenuates Cardiac Dysfunction in Diabetes

If our findings reported here are reproduced in clinical studies, our study may have important clinical implications in the way these drugs should be administered in cardiac dysfunction (Journal of Diabetes Research)


Association between Vitamin D Metabolism Gene Polymorphisms and Risk of Islet Autoimmunity and Progression to Type 1 Diabetes: The Diabetes Autoimmunity Study in the Young (DAISY)

DHCR7/NADSYN1 rs12785878 and CYP27B1 rs4646536 may play an important role in islet autoimmunity, the preclinical phase of T1D. These findings should be replicated in larger cohorts for confirmation (Journal of Clinical Endocrinology & Metabolism)


Monday, 26 August 2013

Do we need continuous glucose monitoring in type 2 diabetes?

Although the studies on the economic feasibility to use CGM as an educational tool must be carried out, we suggest that it can be used as a powerful motivational device to change patients’ lifestyle and to improve glycaemic control in type 2 diabetes (Diabetes/Metabolism Research and Reviews)



Saturday, 24 August 2013

Coxsackievirus B1 Is Associated With Induction of ß-Cell Autoimmunity That Portends Type 1 Diabetes

These results support previous observations suggesting that the group B Coxsackieviruses are associated with the risk of type 1 diabetes (Diabetes)



Synthesis and volume phase transition of concanavalin A-based glucose-responsive nanogels

Glucose-responsive polymer nanogels that can undergo a reversible and rapid volume phase transition in response to the fluctuation in blood glucose concentration have the potential to regulate delivery of insulin mimicking pancreas activity. We report here such a glucose-responsive polymer nanogel, which is made of Concanavalin A (ConA) interpenetrated in a chemically-crosslinked network of poly(N-isopropylacrylamide) (poly(NIPAM)) (Polymer Chemistry)



Plant protein regulates diabetes treatment

A plant protein has been used to make a new class of glucose-responsive polymer nanogels that could one day negate the need for diabetes patients to constantly monitor their blood glucose levels and inject themselves with insulin (Chemistry World)


Friday, 23 August 2013

Medical and psychological outcomes for young adults with Type 1 diabetes: no improvement despite recent advances in diabetes care

We need to learn from European centres who achieve better results, improve transition from paediatric care, integrate mental health support with diabetes care provision and take into account young people's views about clinic (Diabetes Care)



Branched chain and aromatic amino acids change acutely following two medical therapies for type 2 diabetes mellitus

BCAA/AAAs changed acutely during glipizide and metformin administration, and the magnitude and direction of change differed by the insulin resistance status of the individual and the intervention. These results indicate that BCAA/AAAs may be useful biomarkers for monitoring the early response to therapeutic interventions for T2D (Metabolism - Clinical and Experimental)



Statin use and lower extremity amputation risk in nonelderly diabetic patients

This is the first study to report a significant association between statin use and diminished amputation risk among patients with diabetes (Journal of Vascular Surgery)



Antipsychotics and the Risk of Type 2 Diabetes Mellitus in Children and Youth

Children and youth prescribed antipsychotics had an increased risk of type 2 diabetes that increased with cumulative dose (JAMA Psychiatry)


Thursday, 22 August 2013

Diabetes and Healthy Eyes Toolkit

The Diabetes and Healthy Eyes Toolkit provides community health workers with tools to inform people with diabetes about diabetic eye disease and maintaining healthy vision. The toolkit has a flipchart that is easy to use in community settings and can be incorporated into existing diabetes classes or information sessions (National Eye Institute)



Wednesday, 21 August 2013

Diabetes and cancer – an AACE/ACE consensus statement

This document represents the official position of the American Association of Clinical Endocrinologists and the American College of Endocrinology



Empagliflozin As Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes

Empagliflozin 10 and 25 mg for 24 weeks as add-on to metformin plus sulfonylurea improved glycemic control, weight, and systolic blood pressure and were well tolerated (Diabetes Care)



Glucose-Reducing Effect of the ORMD-0801 Oral Insulin Preparation in Patients with Uncontrolled Type 1 Diabetes: A Pilot Study

The observed 16.6% reduction in glycemia will prove clinically relevant if shown to translate to a similar reduction in both HbA1c concentrations and risk of diabetes-related complications in longer trials (PLoS ONE)



ABCD position statement on GLP-1 based therapies and pancreatic damage

We suggest that clinicians review patients on these therapies and ensure that the choice to start them over traditional therapies was based on sound therapeutic and patient centred goals, and that reasonable benefits have been achieved; this being a maxim that can be applied to any newer treatment (ABCD)



Tuesday, 20 August 2013

Hypo Awareness Week, September 9th to 13th 2013

Last year NHS Diabetes organised the first ever national Hypo Awareness Week to raise the profile of hypoglycaemia amongst people with diabetes. As NHS Diabetes has now sadly closed and because we're passionate about improving diabetes care, Spirit Healthcare will now run Hypo Awareness Week (Spirit Healthcare)

Monday, 19 August 2013

Chronic fatigue in type 1 diabetes: highly prevalent but not explained by hyperglycaemia or glucose variability

Chronic fatigue is highly prevalent and clinically relevant in DM1. Its significant relationship with cognitive-behavioral variables and weak association with blood glucose levels suggests that behavioral interventions could be helpful in managing chronic fatigue in DM1 (Diabetes Care)
Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentration in Routine Clinical Care

Interindividual variability in statin exposure in patients is associated with uptake and efflux transporter polymorphisms. An algorithm incorporating genomic and clinical variables to avoid high atorvastatin and rosuvastatin levels is described; further study will determine if this approach reduces incidence of statin-myopathy (Circulation: Cardiovascular Genetics)
Long-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case–control study

This is the longest and largest study of insulin pump use in children and demonstrates that pump therapy provides a sustained improvement in glycaemic control, and reductions of severe hypoglycaemia and hospitalisation for DKA compared with a matched cohort using injections (Diabetologia)

Sunday, 18 August 2013

Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans

Circulating GLP-1 was found to be positivity associated with coronary atherosclerosis in humans. The clinical relevance of this observation needs further investigation (Cardiovascular Diabetology)

Friday, 16 August 2013

Genalyte Launches Multiplexed Biomarker Panel that Measures Seven Autoantigens Associated with the Development of Type 1 Diabetes

The Genalyte T1D antigen panel is the first multiplexed assay that measures seven autoantibodies associated with the destruction of pancreatic islet cells seen in type 1 diabetes (Genalyte)
Risk of breast cancer by individual insulin use - an international multicenter study

This international study found no difference in the risk of developing breast cancer in patients with diabetes among the different types of insulin with short- to mid-term duration of use (Diabetes Care)
Diabetes first for Royal Cornwall Hospital drug trail

Researchers at the Royal Cornwall Hospitals Trust have signed up the first UK patient to take part in a world-wide trial of a new medication that could help with the control of diabetes
Spirit offers value amid soaring diabetes costs

Spirit Healthcare chief executive Chris Barker said:"Companies need to show a bit more responsibility and ensure they are offering the best possible value for money. We work hard to ensure we can deliver the best possible product at the best possible price. It's in everyone's interests to help the NHS, we're all in the same industry and have the same goals, helping patients." (Spirit Healthcare)
In antibody-positive first-degree relatives of patients with type 1 diabetes, HLA-A*24and HLA-B*18, but not HLA-B*39, are predictors of impending diabetes with distinct HLA-DQ interactions

These results reinforce the importance of HLA class I alleles in disease progression and quantify their added value for preparing prevention trials (Diabetologia)
Short Leukocyte Telomere Length Predicts Risk of Diabetes in American Indians

These findings suggest a nonlinear association between LTL and incident diabetes, and indicate that LTL could serve as a predictive marker for diabetes development in American Indians, who suffer from disproportionately high rates of diabetes. (Diabetes)


Thursday, 15 August 2013

Positive Data from a Phase 3 Clinical Study of AFREZZA in Patients with Type 1 Diabetes

In general, treatment with AFREZZA (an inhalation Powder) was well-tolerated over 24 weeks by subjects with type 1 diabetes. The incidence of serious adverse events related to study drug was similar in the AFREZZA-Gen2 (2.3%), AFREZZA-MedTone (2.9%) and insulin aspart (1.8%) groups. (MannKind Corporation)
Glucose testing strips recalled over false reading worry (BBC)

They are GlucoMen LX Sensor blood glucose test strips for use with the GlucoMen LX and GlucoMen LX PLUS blood glucose meter



Wednesday, 14 August 2013

Grafix® Demonstrates Overwhelming Efficacy in Landmark Stem Cell Study for the Treatment of Diabetic Foot Ulcers

Grafix closes three times as many wounds as standard of care - the largest relative improvement ever reported in a multi-center, randomized, controlled clinical trial for DFU (BioSpace)
Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria

Early decline is the primary disease process leading to impaired renal function in T1D. Changes in AER, such as the onset of microalbuminuria, or its progression to macroalbuminuria, are either caused by or develop in parallel to the early renal decline (Diabetes Care)


A New Strategy for Early Diagnosis of Type 2 Diabetes Mellitus by Standard-Free, Label-Free LC-MS/MS Quantification of Glycated Peptides

3 out of the 8 glucose-sensitive peptides (FKDLGEENFK, LDELRDEGK, and KVPQVSTPTLVEVSR) were selected and could be used as potential biomarkers for the early diagnosis of type 2 diabetes mellitus (Diabetes)


Inhibition of Src Kinase Blocks High Glucose-Induced EGFR Transactivation and Collagen Synthesis in Mesangial Cells and Prevents Diabetic Nephropathy in Mice

These data indicate a role for Src in a HG-Src-TACE-HB-EGF-EGFR-MAPK signaling pathway to collagen accumulation. Thus, Src may provide a novel therapeutic target for diabetic nephropathy (Diabetes)
'Largest-ever’ diabetes awareness campaign to urge high-risk patients to visit their GP

The Diabetes UK two-week campaign - the largest the charity has ever run - will be rolled out in September through over 5,000 pharmacies in areas with populations known to be at high risk of type 2 diabetes, in particular those with large black and ethnic minority populations and high levels of deprivation (Pulse)



Inhibition of Src Kinase Blocks High Glucose-Induced EGFR Transactivation and Collagen Synthesis in Mesangial Cells and Prevents Diabetic Nephropathy in Mice


These data indicate a role for Src in a HG-Src-TACE-HB-EGF-EGFR-MAPK signaling pathway to collagen accumulation. Thus, Src may provide a novel therapeutic target for diabetic nephropathy (Diabetes)

Tuesday, 13 August 2013

Prescribing for Diabetes,England 2005-06 to 2012-13

The prescribing data covers prescriptions written by general practitioners, nurses, pharmacists and others working in primary care (Health and Social Care Information Centre)
Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial

In elderly patients with type 2 diabetes linagliptin was efficacious in lowering glucose with a safety profile similar to placebo. These findings could inform treatment decisions for achieving individualised glycaemic goals with minimal risk in this important population of patients (The Lancet)


Efficacy and safety of initial combination of DPP-IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: a systematic review of randomized controlled trials

Compared with equal-dosage metformin monotherapy, the initial combination of metformin and DPP-IV inhibitors were more effective in glycemic control without additional risk of adverse events, therefore it can be considered as a beneficial therapeutic regimen for drug-naïve type 2 diabetes patients (Diabetes, Obesity and Metabolism)

Friday, 9 August 2013

Novo says three year wait for Tresiba safety data

It will be two to three years before Novo Nordisk will be able to present data from a cardiovascular safety study for its insulin degludec Tresiba in people with diabetes (PMLiVE)

Thursday, 8 August 2013

More intestinal cells can absorb larger particles

A new study reports that the small intestine uses more cells than scientists had realized to absorb microspheres large enough to contain therapeutic protein drugs, such as insulin (Brown University)

Wednesday, 7 August 2013

EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. (REGN) and Bayer HealthCare AG (BAY) Report Positive One-Year Results From Two Phase 3 Trials of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema (BioSpace)
Vascular smooth muscle function: defining the diabetic vascular phenotype

This study suggests a novel interpretation for endothelial dysfunction in diabetic patients, indicating VSM cells as key players (Diabetologia)

Glucose-Responsive Microgels Integrated with Enzyme Nanocapsules for Closed-Loop Insulin Delivery

Acting as a self-regulating valve system, microgels were adjusted to release insulin at basal release rates under normoglycemic conditions and at higher rates under hyperglycemic conditions. These microgels with enzyme nanocapsules facilitate insulin release and result in a reduction of blood glucose levels in a mouse model of type 1 diabetes (Nano)


Diabetic Foot Infections: State-of-the-Art

Employing evidence-based guidelines, multidisciplinary teams, and institution-specific clinical pathways provides the best approach to guide clinicians through this multifaceted problem (Diabetes, Obesity and Metabolism)

Tuesday, 6 August 2013

Differences in inpatient glycemic control and response to subcutaneous insulin therapy between medicine and surgery patients with type 2 diabetes

The Basal Plus regimen with glargine once daily and correction doses with glulisine before meals resulted in similar glycemic control to basal bolus regimen. We observed no differences in response to either basal insulin regimen between medicine and surgery patients with type 2 diabetes (Diabetes and Its Complications)

Monday, 5 August 2013

Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis

For the patient to understand how hypoglycemia can be adverse to cardiac function when told to manage hyperglycemia may come as a surprise or sometimes a shock (BMJ)

Sunday, 4 August 2013

Insulin as an Early Treatment for Type 2 Diabetes - ORIGIN or end of an old question?

In summary, the ORIGIN trial could not document CV benefits from early insulin treatment in high-risk patients with recent-onset diabetes while it increases severe and nonsevere hypoglycemia (Diabetes Care)


Early Insulinization to Prevent Diabetes Progression

When one considers initiation of insulin therapy in a type 2 diabetic patient with the intention to preserve ß-cell function, the level of evidence supporting this decision is relatively high ... The place of long-term early insulin treatment in well-controlled type 2 diabetic patients is still debatable. Although the ORIGIN study demonstrated that early insulin therapy with insulin glargine is both safe and feasible, there are still the pros and cons of this treatment to consider (Diabetes Care)


Combining Incretin-Based Therapies With Insulin - Realizing the potential in type 2 diabetes

The improvements in glycemic control may reduce the incidence of diabetes-related complications, and taken together with the reduced risk of hypoglycemia, an incretin plus basal insulin regimen could provide significant health-economic advantages (Diabetes Care)


Early Insulinization to Prevent Diabetes Progression

When one considers initiation of insulin therapy in a type 2 diabetic patient with the intention to preserve ß-cell function, the level of evidence supporting this decision is relatively high ... The place of long-term early insulin treatment in well-controlled type 2 diabetic patients is still debatable. Although the ORIGIN study demonstrated that early insulin therapy with insulin glargine is both safe and feasible, there are still the pros and cons of this treatment to consider (Diabetes Care)


Insulin as an Early Treatment for Type 2 Diabetes - ORIGIN or end of an old question?

In summary, the ORIGIN trial could not document CV benefits from early insulin treatment in high-risk patients with recent-onset diabetes while it increases severe and nonsevere hypoglycemia (Diabetes Care)

Saturday, 3 August 2013

Diabetes Medicines Use Review (MUR) Toolkit

This ‘Diabetes MUR toolkit’ is designed to help improve the confidence of community pharmacy to provide high quality MURs for patients taking diabetes medicines (Devon Local Pharmaceutical Committee)
Albiglutide US PDUFA date extended by three months

The US Prescription Drug User Fee Act (PDUFA) goal date for albiglutide, an investigational once-weekly treatment for adult patients with type 2 diabetes, has been extended by three months to 15 April 2014 to provide time for a full review of information submitted by GSK in response to the Food and Drug Administration’s requests (GSK)


Linagliptin/metformin (Jentadueto®)

Linagliptin/metformin (Jentadueto®) is recommended as an option for use within NHS Wales for the treatment of adult patients with type 2 diabetes mellitus (All Wales Medicines Strategy Group)

Friday, 2 August 2013

Efficacy, usability and sequence of operations of a workflow-integrated algorithm for basal-bolus insulin therapy in hospitalized type 2 diabetes patients

The workflow-integrated algorithm for basal-bolus therapy was effective in establishing glycemic control and was well accepted by medical staff. Our findings support the implementation of the algorithm in an electronic decision support system (Diabetes, Obesity and Metabolism)
Treatment delays linked with 'poor glycaemic control'

Patients with type 2 diabetes experience delays in treatment intensification, often leading to periods of suboptimal glycaemic control, conclude UK researchers (Pulse)

Thursday, 1 August 2013

The Socioeconomic Gradient in Physical Inactivity in England

In this paper we exploit detailed data on over one million individuals in England to more precisely identify and separate the associations between several measures of physical inactivity, different aspects of socioeconomic position and a wide range of local geographical factors. (University of Bristol)
People with diabetes denied vital test strips

People with diabetes are being denied the chance to monitor their blood glucose levels because vital test strips are being rationed to save money, according to a new report by Diabetes UK